AVAVA™ Announces Industry Heavyweights Clint Carnell as Executive Chairman and Mary Fisher to Its Board of Directors [Yahoo! Finance]
Dermata Therapeutics, Inc. (DRMA)
Company Research
Source: Yahoo! Finance
BOSTON, December 17, 2024 BUSINESS WIRE AVAVA™ , a leader in transformative energy-based technology, today announced the appointment of Clint Carnell as Executive Chairman of the Board and Mary Fisher to its Board of Directors. These distinguished industry veterans bring a wealth of experience in scaling high-growth companies, reinforcing AVAVA's commitment to accelerated expansion and increased market share in the medical aesthetics sector. "We are thrilled to welcome Clint and Mary to our Board of Directors," said Irina Erenburg, PhD, Co-Founder, CEO, and Board Member of AVAVA. "Their proven expertise in driving company growth and enhancing shareholder value will be instrumental as we pioneer a new category in medical aesthetics. With boundless energy and fearless vision, we are redefining what's possible with innovative technology." Clint Carnell is a visionary executive with over two decades of leadership in the medical aesthetics industry. As CEO of The HydraFacial Company (
Show less
Read more
Impact Snapshot
Event Time:
DRMA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DRMA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DRMA alerts
High impacting Dermata Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
DRMA
News
- Dermata Receives Approval from FDA for the Proprietary Name Xyngari(TM) [Yahoo! Finance]Yahoo! Finance
- Dermata Receives Approval from FDA for the Proprietary Name Xyngari(TM)Accesswire
- Dermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of Acne [Yahoo! Finance]Yahoo! Finance
- Dermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of AcneAccesswire
- Dermata Completes Enrollment in First Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne [Yahoo! Finance]Yahoo! Finance
DRMA
Sec Filings
- 11/14/24 - Form SC
- 11/14/24 - Form 8-K
- 11/13/24 - Form 10-Q
- DRMA's page on the SEC website